- Home
- ANIX vs FATE Comparison
ANIX vs FATE Comparison
Compare ANIX & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIX | FATE |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 124.6M |
| IPO Year | 1987 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ANIX | FATE |
|---|---|---|
| Price | $3.18 | $1.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $9.00 | $3.92 |
| AVG Volume (30 Days) | 256.6K | ★ 1.6M |
| Earning Date | 01-09-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.12 | $0.66 |
| 52 Week High | $5.46 | $1.94 |
Technical Indicators
Market Signals| Indicator | ANIX | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 62.42 |
| Support Level | $3.07 | $1.02 |
| Resistance Level | $3.36 | $1.09 |
| Average True Range (ATR) | 0.17 | 0.06 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 23.08 | 100.00 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.